Qingqing Cai

4.9k total citations
191 papers, 2.9k citations indexed

About

Qingqing Cai is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Qingqing Cai has authored 191 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Pathology and Forensic Medicine, 60 papers in Oncology and 52 papers in Molecular Biology. Recurrent topics in Qingqing Cai's work include Lymphoma Diagnosis and Treatment (67 papers), Viral-associated cancers and disorders (29 papers) and CAR-T cell therapy research (14 papers). Qingqing Cai is often cited by papers focused on Lymphoma Diagnosis and Treatment (67 papers), Viral-associated cancers and disorders (29 papers) and CAR-T cell therapy research (14 papers). Qingqing Cai collaborates with scholars based in China, United States and Japan. Qingqing Cai's co-authors include Tianxin Lin, Guangzheng Zhong, Wang He, Ken H. Young, Jian Huang, Junhua Luo, Wen Dong, Na Li, Qing Miao and Bijie Hu and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Qingqing Cai

170 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qingqing Cai China 27 1.2k 818 720 571 362 191 2.9k
Shan Li China 31 1.5k 1.2× 1.1k 1.3× 430 0.6× 274 0.5× 548 1.5× 140 3.7k
Nicola Cirillo Australia 34 923 0.8× 632 0.8× 461 0.6× 733 1.3× 348 1.0× 163 3.6k
Lin Shen China 32 1.3k 1.0× 438 0.5× 479 0.7× 379 0.7× 562 1.6× 173 3.6k
Dandan Li China 30 1.4k 1.2× 756 0.9× 498 0.7× 273 0.5× 544 1.5× 153 3.4k
Ravindra Kolhe United States 32 1.6k 1.3× 664 0.8× 726 1.0× 177 0.3× 527 1.5× 147 3.4k
John S. Bomalaski United States 37 1.8k 1.5× 582 0.7× 1.3k 1.8× 187 0.3× 496 1.4× 132 4.8k
Min Kyoung Kim South Korea 26 606 0.5× 765 0.9× 200 0.3× 542 0.9× 328 0.9× 107 2.3k
Shu-Jen Chen Taiwan 31 2.1k 1.7× 360 0.4× 943 1.3× 326 0.6× 342 0.9× 59 4.0k
Junjie Zhao China 33 1.9k 1.6× 718 0.9× 686 1.0× 295 0.5× 1.4k 3.9× 114 4.2k
Ni Tang China 34 2.4k 2.0× 476 0.6× 850 1.2× 182 0.3× 378 1.0× 130 4.1k

Countries citing papers authored by Qingqing Cai

Since Specialization
Citations

This map shows the geographic impact of Qingqing Cai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingqing Cai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingqing Cai more than expected).

Fields of papers citing papers by Qingqing Cai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qingqing Cai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingqing Cai. The network helps show where Qingqing Cai may publish in the future.

Co-authorship network of co-authors of Qingqing Cai

This figure shows the co-authorship network connecting the top 25 collaborators of Qingqing Cai. A scholar is included among the top collaborators of Qingqing Cai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qingqing Cai. Qingqing Cai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Fang, Liang Cheng, Ming Huang, et al.. (2025). Heat shock factor 1 promotes proliferation and chemoresistance in diffuse large B-cell lymphoma by enhancing the cell cycle and DNA repair. Cell Death and Disease. 16(1). 533–533.
2.
Liu, Ling, Qingqing Cai, Liqi Zhu, et al.. (2025). Design of four-level phase-change memory Ge2Sb2Te5/Ge50Te50 bilayer films and study of their crystallization behaviors. Chemical Engineering Journal. 515. 163638–163638.
3.
Liu, Fangfang, et al.. (2024). Effects of different extraction solvents on the major chemical compounds and in vitro biological activities of Dendrobium chrysotoxum Lindl. stems. Industrial Crops and Products. 222. 119678–119678. 5 indexed citations
4.
Zhang, Yuchen, Ning Su, Zhihua Li, et al.. (2024). Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL). Cell Reports Medicine. 5(12). 101833–101833. 4 indexed citations
5.
6.
Cai, Qingqing, Xiaojie Fang, Man Nie, et al.. (2024). TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study. Blood. 144(Supplement 1). 3047–3047.
7.
Yang, Xuena, Shiqiang Cheng, Chuyu Pan, et al.. (2024). Potential involvement of connective tissue growth factor in chondrocytes apoptosis of Kashin-Beck disease. Ecotoxicology and Environmental Safety. 285. 117148–117148. 2 indexed citations
8.
Huang, Liang, Heng Mei, Yuhua Li, et al.. (2024). Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China. Journal for ImmunoTherapy of Cancer. 12(5). e008553–e008553. 10 indexed citations
9.
Zhao, Weili, Jun Zhu, Yuqin Song, et al.. (2024). Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.. Journal of Clinical Oncology. 42(17_suppl). LBA7003–LBA7003. 7 indexed citations
10.
Zhu, Yongzhe, et al.. (2024). Rapid detection of human adenovirus subgroup B using recombinase polymerase amplification assay. Virus Genes. 60(1). 18–24. 3 indexed citations
11.
Du, Ming, Qingqing Cai, Mingxing Zhang, et al.. (2024). Aneuploid serves as a prognostic marker and favors immunosuppressive microenvironment in ovarian cancer. Journal of Ovarian Research. 17(1). 30–30. 1 indexed citations
12.
13.
Su, Ning, Yi Cao, Yi Xia, et al.. (2023). Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. BMC Medicine. 21(1). 423–423. 8 indexed citations
14.
Cai, Qingqing, et al.. (2023). Protein-directed synthesis of fluorescent sulfur quantum dots for highly robust detection of pyrophosphate. Microchimica Acta. 190(3). 104–104. 7 indexed citations
15.
Wang, Qing, Li Lin, Binghua Zhu, et al.. (2023). Case Report: Metagenomic next-generation sequencing applied in diagnosing psittacosis caused by Chlamydia psittaci infection. Frontiers in Cellular and Infection Microbiology. 13. 1249225–1249225. 2 indexed citations
16.
17.
Cai, Jun, Xiao‐Peng Tian, Shu‐Yun Ma, et al.. (2021). A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. British Journal of Cancer. 125(3). 402–412. 11 indexed citations
18.
Tian, Xiao‐Peng, Jun Cai, Shu‐Yun Ma, et al.. (2020). BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T‐cell lymphoblastic lymphoma. Cancer Communications. 40(6). 245–259. 19 indexed citations
19.
Qian, Dong, Kailin Chen, Hui‐Lan Rao, et al.. (2015). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clinical Cancer Research. 21(21). 4881–4891. 55 indexed citations
20.
Huang, Huiqiang, et al.. (2007). Clinical analysis of prognosis for 96 patients with peripheral T-cell lymphoma. Clinical Oncology and Cancer Research. 34(12). 42–45. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shan Li Breakdown of academic impact, for papers by Nicola Cirillo Breakdown of academic impact, for papers by Lin Shen Breakdown of academic impact, for papers by Dandan Li Breakdown of academic impact, for papers by Ravindra Kolhe Breakdown of academic impact, for papers by John S. Bomalaski Breakdown of academic impact, for papers by Min Kyoung Kim Breakdown of academic impact, for papers by Shu-Jen Chen Breakdown of academic impact, for papers by Junjie Zhao Breakdown of academic impact, for papers by Ni Tang
Rankless by CCL
2026